Vimarsana
Biggest News Aggregation in the World

Page 45 - Accessed August News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed August. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed August Today - Breaking & Trending Today

Digital Therapeutics: Challenges Developing & Commercializing DTX Innovations - Vimarsana News

Digital Therapeutics: Challenges Developing & Commercializing DTX Innovations

Transforming a great idea into a Digital Therapeutics (DTx) app that works in healthcare’s complex ecosystem can be painstakingly difficult.

Understanding Alcohol Use and Dementia: From Diagnosis to Patient Education - Vimarsana News

Understanding Alcohol Use and Dementia: From Diagnosis to Patient Education

The role of alcohol in dementia risk still warrants further research on its effects on brain health and better patient education.

Updated Vitrakvi® (larotrectinib) Sub-Analysis at ATA 2021 Supports Efficacy and Safety in Adult and - Vimarsana News

Updated Vitrakvi® (larotrectinib) Sub-Analysis at ATA 2021 Supports Efficacy and Safety in Adult and

Overall response rate (ORR) of 71% (95% confidence interval [CI] 51—87) among those with all types of thyroid cancers (n=28), 86% (95% CI 64—97) among patients with differentiated thyroid cancer (DTC; n=22) and 29% (95% CI 4—71) among patients with anaplastic thyroid cancer (ATC; n=7)1Overall median time to response...

ERLEADA® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates - Vimarsana News

ERLEADA® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA)...

XELJANZ® Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis - Vimarsana News

XELJANZ® Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis

Pfizer Inc. announced today that the European Commission has approved XELJANZ ® for the treatment of active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis in patients two years of age and older who have responded inadequately to previous therapy with disease modifying antirheumatic drugs . Two formulations were approved, a tablet and a new oral solution . XELJANZ is the first and only ...